🇺🇸 CISPLATIN in United States

45,170 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 5,780 reports (12.8%)
  2. Nausea — 5,507 reports (12.19%)
  3. Neutropenia — 4,916 reports (10.88%)
  4. Febrile Neutropenia — 4,634 reports (10.26%)
  5. Vomiting — 4,632 reports (10.25%)
  6. Disease Progression — 4,622 reports (10.23%)
  7. Anaemia — 3,988 reports (8.83%)
  8. Diarrhoea — 3,837 reports (8.49%)
  9. Thrombocytopenia — 3,806 reports (8.43%)
  10. Pyrexia — 3,448 reports (7.63%)

Source database →

CISPLATIN in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is CISPLATIN approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for CISPLATIN in United States?

Marketing authorisation holder not available in our data.